Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
NTNotable Labs, Ltd. logo

Notable Labs, Ltd. (NTBL)

NASDAQ Capital Market · Currency in USD
$0.25 ▼ -0.09 (-27.68%)
At close: Oct 22, 4:00 PM ET. Market closed.
$0.25 ▲ +0.00 (+0.00%)
After hours: Feb 10, 4:00 PM ET

Summary

Previous Close
$0.34
Open
$0.30
Day's Range
$0.24 – $0.31
52 Week Range
$0.22 – $4.24
Volume
1,930,843
Avg. Volume
2,587,565
Market Cap
$2.39M
Beta (5Y Monthly)
-2.36
PE Ratio (TTM)
--
EPS (TTM)
-$5.03
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Notable Labs, Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
16
CEO
Kaile Zagger

Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug. The primary goal of the PPMP is to identify and qualify patients who are expected to respond favorably before they even begin treatment, thereby significantly accelerating the clinical development process for these specific patient groups.

Earnings

DateEst.Actual
Nov 12, 2024-$0.68-$0.48Beat
Aug 14, 2024-$0.43-$0.55Miss
May 15, 2024-$0.39-$0.42Miss
Apr 11, 2024-$0.43-$5.46Miss
Nov 14, 2023-$0.41-$0.48Miss
Aug 14, 2023-$4.90-$0.40Beat

Analyst view

Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on NTBL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.